Comparing ADalimimab to standard immunosuppressive treatments for uveitis
ADalimimab Vs conventional ImmunoSupprEssion for uveitis (ADVISE) Trial
This study is looking at whether ADalimimab, a new type of medicine, works better than traditional treatments for uveitis, an eye condition that can cause vision problems, and it's for people who are dealing with this condition and want to see if they can get better results with fewer side effects.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Wisconsin-Madison NIH-funded |
| Lab location | 1 site (Madison, United States) |
| Project ID | NIH-10479874 on NIH RePORTER |
What this research studies
This research investigates the effectiveness of ADalimimab, a monoclonal antibody, compared to conventional immunosuppressive therapies for treating uveitis, a serious eye condition that can lead to blindness. Patients with uveitis often receive treatments like corticosteroids and other immunosuppressants, but this trial aims to determine if ADalimimab can provide better visual outcomes with fewer side effects. The study will involve multiple centers and will assess long-term visual health in participants while monitoring safety and efficacy. Patients will be closely monitored throughout the trial to evaluate their response to the treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with non-infectious intermediate, posterior, or panuveitis who require immunosuppressive therapy.
Not a fit: Patients with infectious uveitis or those who do not require immunosuppressive treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatment options for patients suffering from uveitis.
How similar studies have performed: Previous studies have shown promising results with monoclonal antibodies in treating similar inflammatory conditions, indicating potential for success in this approach.
Where this research is happening
Madison, United States
- University of Wisconsin-Madison — Madison, United States (Active)
Researchers
- Principal investigator: Altaweel, Michael M — University of Wisconsin-Madison
- Study coordinator: Altaweel, Michael M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.